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OBJECTIVES: To evaluate the effects of antidepressants and pilocarpine on the quantity of myoepithelial cells and
on the proliferation index of the epithelial cells of rat parotid glands.
INTRODUCTION: Hyposalivation, xerostomia, and alterations in saliva composition are important clinical side effects
related to the use of antidepressants.
METHODS: Ninety male Wistar rats were allocated to nine groups. The control groups received saline for 30 (group
C30) or 60 days (group C60) or pilocarpine for 60 days (group Pilo). The experimental groups were administered
fluoxetine (group F30) or venlafaxine for 30 days (group V30); fluoxetine (group FS60) or venlafaxine (group VS60)
with saline for 60 days; or fluoxetine (group FP60) or venlafaxine (group VP60) with pilocarpine for 60 days. Parotid
gland specimens were processed, and the immunohistochemical expression of calponin and proliferating cell
nuclear anti-antigen on the myoepithelial and parenchymal cells, respectively, was evaluated. Analysis of variance
(ANOVA), Tukey HSD and Games-Howell tests were applied to detect differences among groups (p,0.05).
RESULTS: Compared with the controls, chronic exposure to antidepressants was associated with an increase in the
number of positively stained cells for calponin. In addition, venlafaxine administration for 30 days was associated
with an increase in the number of positively stained cells for proliferating cell nuclear anti-antigen. Fluoxetine and
pilocarpine (group FP60) induced a significant decrease in the number of positively stained cells for calponin
compared with all other groups.
CONCLUSIONS: The number of positively stained cells for calponin increased after chronic administration of
antidepressants. The proliferation index of the epithelial cells of rat parotid glands was not altered by the use of
antidepressants for 60 days.
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INTRODUCTION
The current generation of antidepressants includes drugs
that only act on one neurotransmitter, such as the serotonin
(fluoxetine) or the noradrenaline (reboxetine) selective
reuptake inhibitors, and drugs that that act on multiple
neurotransmitters (venlafaxine) without targeting other
cerebral receptors that are not related to depression, such
as histamine and acetylcoline.
1-2 Venlafaxine is a serotonin
and noradrenaline reuptake inhibitor, and it exerts a weak
activity as a dopamine reuptake inhibitor, which is
only clinically significant at high doses.
3,4 The current
antidepressants differ from the classic tricyclic antidepres-
sants and from the monoamine oxidase inhibitors, which
are irreversible, because of their enhanced pharmacological
selectivity and diminished side effects.
5
In a Cochrane systematic review (1966-2004), the adverse
effects of fluoxetine (dry mouth sensation, dizziness, and
sudoresis) were compared with the adverse effects of the
most recent antidepressants (venlafaxine, reboxetine, phe-
nelzine, and nefazodone), and the adverse effects were
shown to be less pronounced in the more recent drugs.
6
Xerostomia is defined as a subjective sensation of dry
mouth reported by the patient. It can result from a reduction
in saliva secretion, but it can also occur in the presence of a
normal salivary flow rate.
7 Stimulated salivary flow rate
(SSFR) values of #0.7 mL/min are considered to indicate
hyposalivation.
8 Hyposalivation, xerostomia, and altera-
tions in the saliva composition are important side effects
related to the use of psychotropic medications, including
Copyright  2011 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2011;66(9):1605-1610 DOI:10.1590/S1807-59322011000900017
1605antidepressants.
7,9-14 The mechanism by which these side
effects occur has still not been completely clarified; how-
ever, histomorphometric and gravimetric studies have
contributed to a better understanding of the cytotoxic effects
of psychotropic drugs on the salivary glands.
12-15
Gre ´gio et al.,
12 studied the effects of chronic administra-
tion of a benzodiazepine (diazepam) and an antidepressant
(amitryptiline) on the parotid glands of rats and observed
hyposalivation and hypertrophy of the serous cells. These
findings suggested a possible inhibition of the activity of the
myoepithelial cells (originating from nervous stimulation), a
decrease in the number of myoepithelial cells following
chronic administration of psychotropic drugs, or an altera-
tion in the number of acinar and ductal cells.
The myoepithelial cells, which are located between the
basal lamina and the plasmatic membrane of the acinar cells
and intercalated ducts, are nonmuscular cells that exert
contractile functions and contribute to the emptying of the
secretion from the secretory units and the ducts.
16,17
Calponin (C) is a protein located in myoepithelial cells that
is involved in the regulatory system of smooth muscle
contraction.
18 Acinar and ductal cells are epithelial cells
with proliferative potential for maintenance and regenera-
tion.
19-23
The aim of this study was to evaluate the quantity of
myoepithelial cells and the proliferation index of acinar and
ductal cells of the parotid glands of rats treated with
fluoxetine and venlafaxine using immunoreactions with
calponin and proliferating cell nuclear anti-antigen (PCNA).
MATERIALS AND METHODS
This study was approved by the Research Ethics
Committee at Universidade Tuiuti do Parana ´ (CEP-UTP n.
55/2003).
Parotid glands from male Wistar rats (Rattus norvegicus
albinus, Rodentia, mammalian) with an approximate weight of
250 g were embedded in paraffin blocks from Laborato ´rio
de Patologia Experimental, Pontifı ´cia Universidade Cato ´lica
do Parana ´. Ninety animals were allocated to nine groups,
and each group was composed of ten animals. The animals
received different treatments, which are described in
Table 1.
15
We used tissue microarrays (TMAs) containing ten
cylinders of paraffinized salivary glands (3 mm in diameter)
organized in lines and columns.
24,25 Each TMA exhibited
ten specimens of salivary glands from the rats of each
group.
For immunohistochemistry, anti-calponin, and anti-PCNA
(DakoCytomationH; Dako North America, Carpinteria, CA,
USA) antibodies were used. The secondary antibody was
EnVisionH+Dual Link/Peroxidase (DakoCytomationH), and
the antigen-antibody reactions were revealed with a DAB
substrate-chromogen system (DakoCytomationH). The slides
were counterstained with Harris hematoxylin.
We used an anti-calponin (C) monoclonal antibody (Dako
Corporation) for myoepithelial cell staining and an anti-
PCNA antibody (Dako Corporation) for the staining of
proliferating acinar and ductal cells. PCNA is a monoclonal
antibody that allows the study of cell kinetics. The
immunoreactions with C and PCNA used antibody dilu-
tions of 15800 and 15400, respectively.
Slides were visualized by only one examiner using an
OlympusH BX50 optical microscope (Olympus Corporation,
Ishikawa, Japan) with a 40X objective. The immunohisto-
chemical expression of C in the myoepithelial cells and
PCNA in the acinar and ductal cells was analyzed by
interpreting the entire TMA area.
The presence or absence of PCNA and C antibody
staining was evaluated. Cells that exhibited any expression
for PCNA or for C in the glandular epithelium were
considered positive (represented by a brownish staining)
regardless of the staining intensity.
There were 24 histological fields in each cylinder of
paraffinized tissue. Before counting the number of stained
cells, we verified the number of fields (out of 24) that could
be evaluated. Therefore, the integrity and quality of the
tissue and the presence of technical artifacts were taken into
consideration. After evaluating the 24 histological fields of
all cylinders, the numerical indices for the positive staining
of cells for C and for PCNA were obtained.
To determine the average value of stained cells for C and
PCNA from each cylinder, the average value of stained cells
in a cylinder was represented by the sum of the number of
stained cells for the antibody in each evaluated field divided
by the number of evaluated fields. After obtaining the
Table 1 - Control and experimental groups according to the drugs used.
Group N Drugs Period of treatment (days) Dose Administration
1- C30 10 Saline 1-30 0.1 mL Intraperitoneal
2- C60 10 Saline 1-60 0.1 mL Intraperitoneal
3- Pilo 10 Pilocarpine
1 1-60 0.05 mL Topical
4- F30 10 Fluoxetine
2 1-30 20 mg/kg Intramuscular
5- V30 10 Venlafaxine
3 1-30 40 mg/kg Intramuscular
6- FS60 10 Fluoxetine 1-30 20 mg/kg Intramuscular
Saline 31-60 0.1 mL Intraperitoneal
7- VS60 10 Venlafaxine 1-30 40 mg/kg Intramuscular
Saline 31-60 0.1 mL Intraperitoneal
8- FP60 10 Fluoxetine 1-30 20 mg/kg Intramuscular
Fluoxetine + Pilocarpine 31-60 20 mg/kg/0.05 mL Intramuscular and Topical
9- VP60 10 Venlafaxine 1-30 40 mg/kg Intramuscular
Venlafaxine + Pilocarpine 31-60 40 mg/kg/0.05 mL Intramuscular and Topical
N = sample size.
1Gel base prepared with 1% pilocarpine hydrochloride (Gerbras Quı ´mica e Farmace ˆutica Ltda., Sa ˜o Paulo, Brazil).
2Injectable fluoxetine (20040625, Galena Quı ´mica e Farmace ˆutica Ltda., Campinas, Brazil).
3Injectable venlafaxine (D/VN/002/02, Galena Quı ´mica e Farmace ˆutica Ltda., Campinas, Brazil).
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1606average value for each cylinder, the values were added
together and divided by ten (equivalent to the total number
of TMAs), which resulted in the average value of stained
cells for each group.
In addition to the C and PCNA variables, this study also
used the average values for the SSFR and cellular volume
(CV) determined in a study by da Silva et al.
15 Because the
present study investigated the same sample as the da Silva
et al. study, the SSFR and CV findings were compared with
the immunohistochemical staining results for C and PCNA.
Statistical analysis
The data were analyzed using Statistical Package for
Social Sciences (SPSS) software version 15.0 for Windows.
The normality analysis was performed using the
Kolmogorov-Smirnov test, and the Levene test was used
to analyze the variance of homogeneity. For the groups with
a normal distribution, analysis of variance (ANOVA) at one
criterion was performed. When ANOVA at one criterion
showed differences among the groups and treatment, the
Tukey HSD multiple comparison test was used for the
variables that presented variance of homogeneity among the
groups. For the variables that did not present variance
homogeneity, the Games-Howell test was used. The level of
significance for all the statistical tests was set at 5% (p,0.05).
RESULTS
Three out of nine groups (C30, F30, and V30) were treated
for 30 days, and six groups (C60, Pilo, FS60, VS60, FP60, and
VP60) were treated for 60 days. The studied variables were
C and PCNA, and they were compared with the CV and
SSFR variables.
15
Groups treated for 30 days
Table 2 shows the average values, standard deviations,
and p-values for the studied variables in the groups treated
for 30 days (C30, F30, and V30). There were significant
differences among the groups treated for 30 days for the
SSFR, CV, PCNA, and C variables (p,0.05).
Compared with the control group (C30), there was a
significant increase in the number of myoepithelial cells
(positively stained cells for C) in the groups treated with
antidepressants (V30 and F30) (p,0.05). In addition, there
was a significant increase in the number of positively
stained cells for PCNA in the group treated with venlafax-
ine (V30) compared with the C30 and F30 groups (p,0.05).
SSFR was significantly decreased in the experimental
(V30 and F30) groups compared with the control group
(p,0.05). Conversely, the highest average values for CV
were observed in groups F30 and V30.
Groups treated for 60 days
Table 3 shows the average values, standard deviations
and p-values for the studied variables in the groups treated
for 60 days (C60, Pilo, FS60, VS60, FP60, and VP60).
There were significant differences among the groups
treated for 60 days for the CV, SSFR, and C variables
(p,0.05).
There was a significant increase in the number of
positively stained cells for C in the group treated with
fluoxetine and saline (FS60) compared with the control
group (C60) (p=0.0258). In addition, there was a significant
decrease in the number of myoepithelial cells in group FP60
compared with all groups (p,0.05).
SSFR was significantly increased in the group treated
with venlafaxine and pilocarpine (VP60) compared with the
group treated with venlafaxine and saline (VS60)
(p=0.0214). In addition, the highest SSFR average value
was found in the Pilo group. Moreover, the lowest average
value for CV was found in the Pilo group, whereas the
highest CV value was found in the VP60 group (p,0.05).
Figures 1-4 illustrate photomicrographs of the parotid
glands of the rats in the experimental and control groups.
DISCUSSION
The anticholinergic actions of psychotropic drugs have
not been completely clarified. Many studies have suggested
that central nervous system (CNS) drugs have pharmaco-
logical actions on the salivary glands. The attempts to clarify
the xerostomic effects of such drugs have been of great
scientific value, both in explaining the physiopharmacolo-
gical effects and in bringing additional benefits to patients
using these drugs.
In the present study, the chronic use of fluoxetine and
venlafaxine for 30 days was associated with a decrease in
SSFR, an increase in CV and an increase in the number of
myoepithelial cells in rats. In addition, venlafaxine was
associated with an increase in acinar and ductal cell
proliferation in the parotid glands. Interestingly, the use of
pilocarpine with venlafaxine for 60 days re-established a
normal SSFR in rats. The number of myoepithelial cells
remained stable in the parotid glands of rats that were
treated for 60 days with venlafaxine irrespective of whether
it was administered with saline or pilocarpine. Pilocarpine
used in association with fluoxetine for 60 days did not
induce changes in SSFR, but it was associated with a severe
Table 2 - Mean values (X) and standard deviations (SD) of the studied variables in the groups treated for 30 days with
saline (C30), fluoxetine (F30), or venlafaxine (V30).
Groups C30 F30 V30 p-value
XS D X S DXS D
SSFR (mL/min)
d 0.051¡0.026
a,b 0.014 ¡ 0.006
a 0.026 ¡ 0.022
b 0.001*
CV (mm
3)
d 6,965.683¡3,792.951
a,b 10,384.311¡4,869.539
a 11,945.927¡7,891.179
b 0.000*
PCNA 55.8¡14.382
a 59.4¡16.900
b 89.5¡16.400
a,b 0.000*
C 13.9¡2.644
a,b 20¡4.216
a 19.8¡5.007
b 0.003*
dValues obtained from the study by da Silva et al. (2009)
15.
SSFR – stimulated salivary flow rate; CV – cellular volume; PCNA – proliferating cell nuclear antigen; C – calponin.
a,bGroups followed by the same letter differed statistically from each other.
*Statistically significant difference among groups (p,0.05).
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1607decrease in the number of myoepithelial cells in the parotid
glands of rats. Considering these results, three main points
must be discussed: the mechanisms of action of the
medications on the CNS, physiological adaptation to the
use of psychotropic medications, and alterations in receptor
sensitivity due to the chronic use of medication.
Fluoxetine and venlafaxine have anticholinergic effects of
different intensities. Because fluoxetine is a selective
serotonin reuptake inhibitor, it may cause greater serotonin
availability in the synaptic gap, which alters the binding of
acetylcholine to the muscarinic receptors (M3) present in the
salivary glands. Thus, fluoxetine may decrease the quantity
of salivary secretion. Venlafaxine is an atypical antidepres-
sant and acts as a reuptake inhibitor of serotonin,
noradrenaline, and dopamine.
11 Venlafaxine does not show
affinity for a1 adrenergic receptors, M3 muscarinic recep-
tors, or histamine receptors. Interestingly, the actions of
venlafaxine become unpredictable because it can act
through multiple targets, which can elicit results ranging
from a decrease in salivary secretion to alterations
in salivary composition.
13,21 Although antidepressant
medications do not seem to block saliva production, they
interfere with the binding of acetylcholine to M3 receptors.
Thus, saliva is produced, but it cannot be excreted.
12
Compared with the control groups (C30), the increase in
CV values in the parotid glands of rats that received
antidepressants for 30 days (groups F30 and V30) appeared
to represent acinar and ductal cell hypertrophy. Serous cell
hypertrophy, which is characterized by widened acinar cells
and secretory granule accumulation, has previously been
reported following the chronic use of psychotropic
drugs.
12,26
The present study showed the anticholinergic effects of
chronic fluoxetine and venlafaxine administration for 30
days . With 60-day treatment, the SSFR reduction was not
significantly different than the control group. Studies have
shown that the prolonged use of psychotropics causes
alterations in receptor sensitivity.
24 In addition, therapeutic
effects and side effects gradually decrease after continuous
or repeated psychotropic administration, which may cause
desensitization, resistance, or tolerance. Physiological adap-
tation may also occur, and many side effects of drugs tend
to diminish over time despite continuous use of a drug.
27
Therefore, the least pronounced SSFR decrease in rats
treated for 60 days may be a consequence of tolerance or
adaptation to psychotropic drugs.
The absence of a significant difference in the mean SSFR
values among the C60, FS60, and VS60 groups suggested
that the normal SSFR of the rats was re-established 30 days
after suspending the medication (Table 3). These data must
be carefully analyzed, however, because a decrease in SSFR
Table 3 - Mean values (X) and standard deviations (SD) of the studied variables in the groups treated for 60 days with
saline (C60), pilocarpine (Pilo), fluoxetine and saline (FS60), venlafaxine and saline (VS60), fluoxetine and pilocarpine
(FP60), or venlafaxine and pilocarpine (VP60).
Groups C60 PILO FS60 VS60 FP60 VP60 p- value
X SD X SD X SD X SD X SD X SD
SSFR
(mL/min)
d
0.052¡0.029 0.067¡0.028
a,b 0.036¡0.017 0.020¡0.004
a,c 0.034¡0.014
b 0.055¡ 0.026
c 0.000*
CV
(mm
3)
d
6,505.564¡
3,343.475
d
5,825.418¡
1,968.070
ab
6,809.347¡
3,189.246
e
7,525.112¡
3,196.085
ac
7,519.797¡
4,272.808
f
10,194.315¡
4,456.345
b,c,d,e,f
0.000*
PCNA 50¡17.531 46.8¡13.506 36.7¡16.687 52.5¡18.710 52¡17.153 43.6¡18.007 0.296
ns
C 13.6¡4.789
c,f 22.1¡7.385
a 24.2¡7.955
b,c 19.7¡4.322
d 7¡1.563
a,b,d,e,f 18.2¡6.250
e 0.000*
dValues obtained from the study by da Silva et al. (2009)
15.
SSFR – stimulated salivary flow rate; CV – cellular volume; PCNA – proliferating cell nuclear antigen; C – calponin.
a,b,c,d,e,fGroups followed by the same letter differed statistically from each other.
*Statistically significant difference among the groups (p,0.05).
ns– No statistically significant difference among the groups (p.0.05).
Figure 1 - Rat parotid gland with normal parenchyma.
Immunohistochemical staining of PCNA on epithelial cells (C60,
original magnification 400X).
Figure 2 - Immunohistochemical staining of PCNA on epithelial
cells (FP60, original magnification 400X).
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1608greater than 50% brings relevant prejudicial consequences
(C60 – 0.052 mL/min; VS60 – 0.020 mL/min).
SSFR reduction in rats undergoing chronic treatment with
fluoxetine may still be an indirect consequence of serotonin
action at the 5-HT (5-hydroxytryptamine) receptors present
in peripheral microcirculation. Indeed, fluoxetine increases
serotonin availability, and serotonin may bind to 5-HT
receptors, which would alter the blood flow in the salivary
glands and, consequently, the quantity and composition of
the salivary flow.
28
In the present study, pilocarpine exerted a significant
secretagogue effect, which showed its cholinergic agonist
capacity and corroborated the findings of Davies and
Shorthose.
29 Pilocarpine was associated with an increase in
SSFR and efficiently treated the hyposalivation caused by
venlafaxine (groups VS60 and VP60). Conversely, when
pilocarpine was used in association with fluoxetine (group
FP60), there was no SSFR increase compared with the group
that did not receive pilocarpine (group FS60 – Table 3).
Pilocarpine is a parasympathomimetic agent that acts as a
nonselective muscarinic receptor agonist.
30,31 Thus, pilocar-
pine promotes stimulation of the exocrine glands and
salivary secretion, which is efficient for patients without
extensive glandular parenchymal destruction.
30
In the present study, chronic administration of either
fluoxetine or venlafaxine for 30 days was associated with an
increase in the number of myoepithelial cells in the parotid
glands of rats. These results contradict Gre ´gio et al.
12 who
suggested that the hyposalivation and serous cell hyper-
trophy observed after chronic treatment with benzodiaze-
pines and antidepressants in rats could be explained by a
decrease in the number of myoepithelial cells.
12 We
hypothesized that a deficit in saliva elicits a compensatory
activity that increases the number of myoepithelial cells,
which have contractile functions, to assist in releasing the
retained saliva. The myoepithelial cells accelerate the initial
saliva emptying flow rate and promote the drainage of any
adjacent extracellular fluid. The dendrites of the myoepithe-
lial cells fold around the duct system, and their function is
to compress the acinar and ductal cells.
16,17
The parenchymatous cells (i.e., acinar, myoepithelial, and
ductal) show a proliferative potential for maintenance and
regeneration of the adult parenchymatous cell population in
normal glands. In addition, parenchymatous cells show a
proliferative capacity when submitted to physical injury,
such as ductal obstruction.
19,20,32,33
This study was performed because there were no
immunohistochemical studies of myoepithelial, acinar and
ductal cells following the use of psychotropic drugs. There
have been immunohistochemical studies on the proliferative
capacity of parenchymatous cells in induced glandular
atrophy,
19,22,23,33 and a comparative analysis between the
present study and the studies of induced glandular atrophy
may be established. Interestingly, an animal model of
induced atrophy of the parotid gland’s main duct did not
prevent the gland from producing saliva. This saliva,
however, was not excreted due to a physical obstruction
in the main excretory duct. In an animal model of chronic
antidepressant administration, we suggested that the saliva
was continuously produced, but it was not secreted because
of neurochemical interference from the psychotropic drugs.
In animal models submitted to injuries (physical and
neurochemical), there were significant increases in the
number of myoepithelial cells.
22,23,33
Because calponin is not a cellular proliferation marker,
this study determined the numerical index of positively
stained cells for calponin, which specifically identifies the
myoepithelial cells in the glandular parenchyma. Due to the
methodology that was employed, it was not possible to
directly infer the cell proliferation, but it was possible to
suggest that there was an alteration in the myoepithelial
cellular proliferation rate among the studied groups.
In the groups of rats treated for 30 days, venlafaxine (V30)
seemed to induce an increase in acinar and ductal cell
proliferation compared with saline (control group). In an
attempt to compensate for the significant SSFR reduction
that resulted from the chronic use of venlafaxine (V30),
mitoses may have occurred to create new acini and ducts
(Table 2). The intense proliferative capacity of acinar and
ductal cells has already been reported in studies of
glandular atrophy induced by obstruction.
19 Moreover, the
V30 group showed the highest mean CV value, which
suggested the presence of cellular hypertrophy. It is worth
emphasizing that there is a critical size for each cell, above
which the stimulus for hypertrophy does not cause
adaptative reactions, and the cell goes through mitosis to
compensate for the excessive cytoplasm.
34 We believe that
the proliferative capacity of the acinar and ductal cells and
the presence of cellular hypertrophy may have contributed
F i g u r e3-Immunohistochemical staining of calponin on
myoepithelial cells (Pilo, original magnification 400X).
F i g u r e4-Immunohistochemical staining of calponin on
myoepithelial cells (V30, original magnification 400X).
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for PCNA in the V30 group.
For the groups treated for 60 days, there were not any
significant differences in PCNA. Generally, chronic use of
antidepressants has not been associated with significant
aggression to the acinar and ductal cells. We believe that
the proliferative potential of acinar and ductal cells assists in
maintaining and regenerating the adult parenchymatous
cellular population.
Although rat models have some limitations, diseases
and/or therapeutic simulations in animal models are
important tools for examining disease prognoses and
investigating the side effects of drugs.
CONCLUSIONS
The number of positively stained cells for C was shown
to be increased with the chronic use of venlafaxine or
fluoxetine. The proliferation index of the epithelial cells of
rat parotid glands, however, was not altered by the use of
antidepressants for 60 days.
ACKNOWLEDGEMENTS
The authors would like to thank the employees of the Laborato ´rio de
Patologia Experimental, Pontifı ´cia Universidade Cato ´lica do Parana ´. This
study was supported by CNPq (grant 474790/2004-5).
REFERENCES
1. Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain
management. Psychiatry (Edgmont). 2008;5:16-9.
2. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human
brain receptors: focus on newer generation compounds. Psycho-
pharmacology (Berl). 1994;114:559-65, doi: 10.1007/BF02244985.
3. Dhir A, Kulkarni SK. Antidepressant-like effect of 17 beta-estradiol:
involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor
systems. Can J Physiol Pharmacol. 2008;86:726-35, doi: 10.1139/Y08-077.
4. Spina E, Santoro V, D9Arrigo C. Clinically relevant pharmacokinetic
drug interactions with second-generation antidepressants: an update.
Clin Ther. 2008;30:1206-27, doi: 10.1016/S0149-2918(08)80047-1.
5. Stahl SM. Psychopharmacology of antidepressants. London: Martin
Dunitz. 1997;114.
6. Cipriani A, Brambilla P, Furukawa TA, Geddes J, Gregis M, Hotopf M,
et al. Fluoxetine versus other types of pharmacotherapy for depression.
Cochrane Database of Systematic Reviews. In: The Cochrane Library.
2006;3.
7. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and
treatment. J Am Dent Assoc. 2003;134:61-9.
8. Tenovuo J. Salivary parameters of relevance for assessing caries activity
in individuals and populations. Community Dent Oral Epidemiol.
1997;25:82-6, doi: 10.1111/j.1600-0528.1997.tb00903.x.
9. Ferguson MM. Pilocarpine and other cholinergic drugs in the manage-
ment of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol.
1993;75:186-91, doi: 10.1016/0030-4220(93)90092-I.
10. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis.
2003;9:165-76, doi: 10.1034/j.1601-0825.2003.03967.x.
11. Keene JJ Jr, Galasko GT, Land MF. Antidepressant use in psychiatry and
medicine: importance for dental practice. J Am Dent Assoc. 2003;134:71-
9.
12. Gre ´gio AMT, Durscki JRC, Lima AAS, Machado MAN, Igna ´cio SA,
Azevedo LR. Association of amitriptyline and diazepam on the
histomorphometry of rat parotid glands. Pharmacologyonline.
2006;2:96-108.
13. de Almeida P del V, Gre ´gio AM, Brancher JA, Igna ´cio SA, Machado MA,
de Lima AA, et al. Effects of antidepressants and benzodiazepines on
stimulated salivary flow rate and biochemistry composition of the saliva.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:58-65, doi:
10.1016/j.tripleo.2007.11.008.
14. Zaclikevis MV, D’Agulham AC, Bertassoni LE, Machado MA, de Lima
AA, Gre ´gio AM, et al. Effects of benzodiazepine and pilocarpine on rat
parotid glands: histomorphometric and sialometric study. Med Chem.
2009;5:74-8, doi: 10.2174/157340609787049262.
15. da Silva S, de Azevedo LR, de Lima AA, Igna ´cio SA, Machado MA,
ZacliKevis MV, et al. Effects of fluoxetine and venlafaxine and
pilocarpine on rat parotid glands. Med Chem. 2009;5:483-90, doi: 10.
2174/157340609789117868.
16. Klein RM. Development, structure and function of the salivary glands.
In: Avery JK. Oral development and histology. USA: New York.
2001;292-331.
17. Berkovitz BKB, Holland GR, Moxham BJ. Oral anatomy, embryology and
histology. Chicago: Mosby. 2002;255-67.
18. Zarbo RJ, Prasad AR, Regezi JA, Gown AM, Savera AT. Salivary gland
basal cell and canalicular adenomas: immunohistochemical demonstra-
tion of myoepithelial cell participation and morphogenetic considera-
tions. Arch Pathol Lab Med. 2000;124:401-5.
19. Burford-Mason AP, Cummins MM, Brown DH, MacKay AJ, Dardick I.
Immunohistochemical analysis of the proliferative capacity of duct and
acinar cells during ligation-induced atrophy and subsequent regenera-
tion of rat parotid gland. J Oral Pathol Med. 1993;22:440-6, doi: 10.1111/j.
1600-0714.1993.tb00122.x.
20. Norberg L, Dardick I, Burford-Mason AP. Differentiating myoepithelial
and acinar cells in rat neonatal parotid gland and histogenetic concepts
for salivary gland tumors. J Oral Pathol Med. 1996;25:474-80, doi: 10.
1111/j.1600-0714.1996.tb00300.x.
21. Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double
blind comparison of venlafaxine and paroxetine in obsessive-compulsive
disorder. J Clin Psychopharmacol. 2003;23:568-75, doi: 10.1097/01.jcp.
0000095342.32154.54.
22. Takahashi S, Schoch S, Walker NI. Origin of acinar cell regeneration after
atrophy of the rat parotid induced by duct obstruction. Int J Exp Pathol.
1998;79:293-301, doi: 10.1046/j.1365-2613.1998.710405.x.
23. Burgess KL, Dardick I, Cummins MM, Burford–Mason AP, Bassett R,
Brown DH. Myoepithelial cells actively proliferate during atrophy of rat
parotid gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
1996;82:674-80, doi: 10.1016/S1079-2104(96)80443-4.
24. Rocha RM, Andrade VP, Nunes CB, Rocha GFS, Sanches FSF, Oliveira
FS, et al. Construc ¸a ˜o de arrays de tecido com equipamento alternativo e
de baixo custo para estudo imuno-histoquı ´mico de tumores mama ´rios.
J Bras Patol Med Lab. 2006;42:477-82, doi: 10.1590/S1676-2444200
6000600012.
25. Schuler S, Gurmini J, Cecı ´lio WA, Viola de Azevedo ML, Olandoski M,
de Noronha L. Hepatic and thymic alterations in newborn offspring of
malnourished rat dams. J Parenter Enteral Nutr. 2008;32:184-9, doi: 10.
1177/0148607108314387.
26. Martinez-Madrigal F, Micheau C. Histology of the major salivary glands.
Am J Surg Pathol. 1989;13:879-99, doi: 10.1097/00000478-198910000-
00008.
27. Gorenstein C, Scavone C. Avanc ¸os em psicofarmacologia - mecanismos
de ac ¸a ˜o de psicofa ´rmacos hoje. Rev Bras Psiquiatr. 1999;2:64-73, doi: 10.
1590/S1516-44461999000100012.
28. Rang HP, Dale MM, Ritter JM, Flower RJ. Pharmacology. London:
Churchill Livingstone. 2007;557-74.
29. Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment
of salivary gland dysfunction due to radiotherapy. Cochrane Database
Syst Ver. 2007;18:19.
30. Grisius MM. Salivary gland dysfunction: a review of systemic therapies.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:156-62, doi:
10.1067/moe.2001.116601.
31. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am
Geriatr Soc. 2002;50:535-43, doi: 10.1046/j.1532-5415.2002.50123.x.
32. Denny PC, Ball WD, Redman RS. Salivary glands: a paradigm for
diversity of gland development. Crit Rev Biol Med. 1997;8:51-75, doi: 10.
1177/10454411970080010301.
33. Miguel MC, Andrade ES, Taga R, Pinto LP, Souza LB. Hyperplasia of
myoepithelial cells expressing calponin during atrophy of the rat parotid
gland induced by duct ligation. Histochem J. 2002;34:499-506, doi: 10.
1023/A:1024761923303.
34. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of
disease. 6th ed. Philadelphia: W. B. Saunders Co. 1999;p.336.
Effects of antidepressants and pilocarpine
Mattioli TMF et al.
CLINICS 2011;66(9):1605-1610
1610